
StudyFinder
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Recruiting
SPR001-204 will be a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have lower limit of detection (LLD) ≤ A4 ≤ 1.5x upper limit of normal (ULN) and are on supraphysiologic doses of GC therapy. SPR001-204 will be the first study of tildacerfont to evaluate GC dose reduction. In addition, Study SPR001-204 will characterize clinical outcomes after up to 52 weeks of treatment with tildacerfont.
18 Years and over
Congenital Adrenal Hyperplasia, Diabetes & Endocrine
Adrenal Disorder, CAH, Congenital Adrenal Hyperplasia, congenital adrenal hyperplasia
Kristin Boxwell - kboxwell@umn.edu
Kyriakie Sarafoglou
Phase II
STUDY00011764
NCT04544410
See this study on ClinicalTrials.gov